Patents by Inventor Nathan Bryan Mantlo
Nathan Bryan Mantlo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8697849Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 2, 2013Date of Patent: April 15, 2014Assignee: Eli Lilly and CompanyInventors: Fucheng Qu, Nathan Bryan Mantlo
-
Publication number: 20130303471Abstract: The present invention provides a compound of Formula II: wherein X represents the following: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 2, 2013Publication date: November 14, 2013Applicant: Eli Lilly and CompanyInventors: Fucheng QU, Nathan Bryan MANTLO
-
Patent number: 8106077Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.Type: GrantFiled: May 22, 2007Date of Patent: January 31, 2012Assignee: Eli Lilly and CompanyInventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M Warshawsky
-
Patent number: 7786108Abstract: Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.Type: GrantFiled: June 23, 2005Date of Patent: August 31, 2010Assignee: Eli Lilly and CompanyInventors: Xinchao Chen, Todd Fields, Nathan Bryan Mantlo, Xiaodong Wang
-
Publication number: 20100204207Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.Type: ApplicationFiled: April 20, 2010Publication date: August 12, 2010Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
-
Patent number: 7749992Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.Type: GrantFiled: October 7, 2004Date of Patent: July 6, 2010Assignee: Eli Lilly and CompanyInventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
-
Publication number: 20100099725Abstract: The present invention is directed to compounds of the structural Formula: wherein: R1 is H or —C1-C3 alkyl; R2 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of —H, —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, CH2—C?CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; provided that when R1 and R2 are each H, then R3 is selected from the group consisting of —C1-C4 alkyl, —C1-C3 alkyl-O—CH3, —CH2-cyclopropyl, —CH2—C?CH2, —CH2CH2-(2-F-phenyl), and phenyl substituted with from 1 to 2 fluorines; or stereoisomers and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: February 12, 2008Publication date: April 22, 2010Inventors: Lance Allen Pfeifer, Tianwei Ma, Nathan Bryan Mantlo, Laura Frey Michael, Fese Mambo Mokube, Chahrzad Montrose-Rafizadeh
-
Patent number: 7655641Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.Type: GrantFiled: February 10, 2004Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
-
Patent number: 7598266Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.Type: GrantFiled: April 9, 2008Date of Patent: October 6, 2009Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, Nathan Bryan Mantlo, Guoxin Zhu
-
Publication number: 20090176863Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30: (c) Y is selected from the group consisting of C, O, S, NH and a single bond; and (d) E is C(R3)(R4)A or A.Type: ApplicationFiled: February 11, 2009Publication date: July 9, 2009Inventors: Nathan Bryan Mantlo, Xiaodong Wang, Guoxin Zhu
-
Patent number: 7544812Abstract: The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4 alkyl sulfonamide, C1-C4 alkyl amide, OR10 and C3-C6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.Type: GrantFiled: November 26, 2002Date of Patent: June 9, 2009Assignee: Eli Lilly and CompanyInventors: Tracey Ann Gibson, Richard Duane Johnston, Nathan Bryan Mantlo, Richard Craig Thompson, Leonard Larry Winneroski, Yanping Xu, Xiaodong Wang
-
Patent number: 7544707Abstract: The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4-heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.Type: GrantFiled: December 16, 2004Date of Patent: June 9, 2009Assignee: Eli Lilly and CompanyInventors: Scott Eugene Connor, Nathan Bryan Mantlo, Guoxin Zhu, Robert Jason Herr
-
Patent number: 7528160Abstract: The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.Type: GrantFiled: December 31, 2003Date of Patent: May 5, 2009Assignee: Eli Lilly and CompanyInventors: Scott Eugene Conner, James Allen Knobelsdorf, Nathan Bryan Mantlo, Daniel Ray Mayhugh, Xiaodong Wang, Guoxin Zhu, Jeffrey Michael Schkeryantz
-
Publication number: 20090093524Abstract: Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.Type: ApplicationFiled: May 22, 2007Publication date: April 9, 2009Inventors: Michael Gregory Bell, Robert Anthony Doti, Matthew Scott Dowling, Michael James Genin, Peter Ambrose Lander, Tianwei Ma, Nathan Bryan Mantlo, Jason Matthew Ochoada, Lindsay Scott Stelzer, Ryan Edward Stites, Alan M. Warshawsky
-
Patent number: 7507832Abstract: The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.Type: GrantFiled: December 21, 2004Date of Patent: March 24, 2009Assignee: Eli Lilly and CompanyInventors: Nathan Bryan Mantlo, Antonio Navarro, Ashraf Saeed, Douglas Linn Gernert, Tianwei Ma, Lance Allen Pfeifer
-
Patent number: 7504433Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; and (d) E is C(R3)(R4)A or A.Type: GrantFiled: December 31, 2003Date of Patent: March 17, 2009Assignee: Eli Lilly and CompanyInventors: Nathan Bryan Mantlo, Xiaodong Wang, Guoxin Zhu
-
Publication number: 20090062358Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy.Type: ApplicationFiled: July 26, 2007Publication date: March 5, 2009Inventors: Ivan Collado Cano, Samuel James Dominianni, Garret Jay Etgen, JR., Cristina Garcia-Paredes, Richard Duane Johnston, Michael Edward Letourneau, Nathan Bryan Mantlo, Michael John Martinelli, Daniel Ray Mayhugh, Ashraf Saeed, Richard Craig Thompson, Xiaodong Wang, David Scott Coffey, Christopher Randall Schmid, Jeffrey Thomas Vicenzi, Yanping Xu
-
Publication number: 20090054479Abstract: The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.Type: ApplicationFiled: April 9, 2008Publication date: February 26, 2009Inventors: Scott Eugene Conner, Nathan Bryan Mantlo, Guoxin Zhu
-
Patent number: 7470705Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.Type: GrantFiled: March 17, 2005Date of Patent: December 30, 2008Assignee: Eli Lilly and CompanyInventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
-
Publication number: 20080269284Abstract: Compounds of Formula I wherein n, q, Y, R1, R2a, R2b, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.Type: ApplicationFiled: June 22, 2005Publication date: October 30, 2008Applicant: ELI LILLY AND COMPANYInventors: Ana Maria Escribano, Maria Carmen Fernandez, Nathan Bryan Mantlo, Ana Isabel Mateo-Herranz, Eva Maria Martin De La Nava, Xiaodong Wang